Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 1 art units • 1 examiners • 0 of 3 (0%) have an AI response strategy ready
Auspex Pharmaceuticals LLC is a company patent portfolio focused on the Biotechnology & Pharmaceuticals technology area. The portfolio currently includes 3 pending office actions. This count of pending actions represents the current state of active prosecution for the entity at the USPTO.
The examination of this portfolio is conducted by 1 distinct examiner within 1 distinct art unit. This concentration means that the company's current prosecution experience is limited to the standards of 1 specific technical group. There are no other pending cases to provide a comparison of examiner behavior or art unit trends for this entity in the Biotechnology & Pharmaceuticals field.
LEE, ANDREW P is the busiest examiner for the portfolio, with 3 pending office actions currently under review. As the only examiner with active cases, their specific evaluation of the technology is the primary factor in the company's current prosecution. Practitioners should focus on the historical patterns and preferences of LEE, ANDREW P across all 3 pending matters.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LEE, ANDREW P | 3 | 48.5% | +22.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19446877 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | LEE, ANDREW P | — |
| 19446867 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | LEE, ANDREW P | — |
| 19446884 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | LEE, ANDREW P | — |
| Art Unit | Apps |
|---|---|
| 1691 | 3 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19446877 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | LEE, ANDREW P | 1691 | §112 | Non-Final OA | — | Pending | Jan 12, 2026 |
| 19446867 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | LEE, ANDREW P | 1691 | §112 | Non-Final OA | — | Pending | Jan 12, 2026 |
| 19446884 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | LEE, ANDREW P | 1691 | §112 | Non-Final OA | — | Pending | Jan 12, 2026 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAuspex Pharmaceuticals LLC has 3 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Andrew P Lee has the most, with 3 of Auspex Pharmaceuticals LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
